Over the last decade, the first-line therapy for n-AMD recommended by the treatment guidelines is the intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (Tamashiro et al., 2022; Wong et al., 2008), including ranibizumab (Lucentis; Genentech, South San Francisco, CA, USA) (Rosenfeld et al., 2006; Brown et al., 2006) and aflibercept (Eylea; Regeneron, Tarrytown, NY, USA, and Bayer HealthCare, Berlin, Germany) (Heier et al., 2012). The gene discussed is VEGFA; the disease is age-related macular degeneration.